Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Daiichi reports Phase III VTE data for edoxaban

Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) said once-daily edoxaban plus heparin met the primary efficacy endpoint of non-inferiority to warfarin plus heparin

Read the full 221 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE